<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00912015</url>
  </required_header>
  <id_info>
    <org_study_id>MDT3-001-E1-A1</org_study_id>
    <nct_id>NCT00912015</nct_id>
  </id_info>
  <brief_title>A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up</brief_title>
  <official_title>A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labopharm Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety (up to one year) of Tramadol
      Once-A-Day (OAD) tablets at the highest doses: 200-400 mg
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events: 12-months Safety Population</measure>
    <time_frame>12 months</time_frame>
    <description>Spontaneous adverse events were recorded for patients who received the same dose for at least 350 days. A treatment emergent adverse event (TEAE) was associated to the dose level on which a patient was 2 days prior to the TEAE. Only TEAEs which could be associated with the dose level on which the patient was for the longest time were considered.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">238</enrollment>
  <condition>Pain</condition>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Tramadol OAD 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol OAD 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol OAD 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol OAD 100mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Despite provision in the protocol that the minimum daily dose was 200 mg, 2 patients took 100 mg against instructions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol OAD</intervention_name>
    <arm_group_label>Tramadol OAD 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol OAD</intervention_name>
    <arm_group_label>Tramadol OAD 300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol OAD</intervention_name>
    <arm_group_label>Tramadol OAD 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol OAD 100mg</intervention_name>
    <arm_group_label>Tramadol OAD 100mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female patients between the ages of 40-75 with a diagnosis of Osteoarthritis
             of the knee consistent with the ACR Clinical Classification Criteria for Arthritis of
             the Knee (Altman, R. et al., 1991):

               -  Current knee pain,

               -  Less than 30 minutes of morning stiffness with or without crepitus on active
                  motion.

               -  Confirmation either by arthroscopy or radiologist's report (X-rays showing
                  osteophytes, joint space narrowing or subchondral bone sclerosis {eburnation})
                  within one year prior to entry into the study.

          2. ESR &lt; 40 mm/hour

          3. WOMAC Pain Subscales total score of more than or equal to 150 mm at baseline.

          4. Oral and written language comprehension at a level sufficient to comply with the
             protocol and complete study-related materials.

          5. The Patient has signed and dated the REB approved, written, informed consent prior to
             study participation.

        Exclusion Criteria:

          1. Known rheumatoid arthritis or any other rheumatoid disease.

          2. Secondary arthritis, i.e. any of the following: septic arthritis; inflammatory joint
             disease; gout; pseudogout; Paget's disease; joint fracture; acromegaly; fibromyalgia;
             Wilson's disease; Ochronosis; Haemochromatosis; Osteochondromatosis; heritable
             arthritic disorders; or collagen gene mutations.

          3. Obesity Class II (BMI more than or equal to 35) (NIH, 2000)

          4. Major illness requiring hospitalization during the 3 months before commencement of the
             screening period.

          5. Unwillingness to cease taking medication other than the study medication for arthritic
             pain, any other concomitant pain, or OA medications.

          6. Patients who have previously failed tramadol HCl therapy or those who discontinued
             tramadol HCl due to adverse events.

          7. Patients who are taking or within the last 3 weeks have taken the following
             medications: monoamine oxidase inhibitors; tricyclic antidepressants and other
             tricyclic compounds (e.g. cyclobenzaprine, promethazine); neuroleptics; selective
             serotonin reuptake inhibitors; or other drugs which reduce seizure threshold.

          8. Patients who are taking or have taken another investigational agent within the last 30
             days.

          9. Patients with a history of seizure disorder other than Infantile Febrile Seizures.

         10. Patients who are opioid dependent.

         11. Patients with bowel disease causing malabsorption.

         12. Patients who are pregnant or lactating or patients of child-bearing potential who are
             unwilling to utilize a medically approved method of contraception during participation
             in this clinical trial.

         13. Patients with significant liver disease, defined as active hepatitis or elevated liver
             enzymes &gt;3 times the upper boundary of the normal range.

         14. Patients with significant renal disease, defined as creatinine clearance &lt;30 mL/min as
             estimated by the method of Levey et al., 1999.

         15. Current substance abuse or dependence, other than nicotine.

         16. Allergy or adverse reaction to tramadol or any structurally similar drugs e.g.
             opiates.

         17. Any other condition that, in the opinion of the investigators, would adversely affect
             the patient's ability to complete the study or its measures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <results_first_submitted>April 9, 2009</results_first_submitted>
  <results_first_submitted_qc>June 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2009</results_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tramadol OAD 200mg</title>
          <description>All Patients who Received 1x200 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
        </group>
        <group group_id="P2">
          <title>Tramadol OAD 300mg</title>
          <description>All Patients who Received 1x300 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
        </group>
        <group group_id="P3">
          <title>Tramadol OAD 400mg</title>
          <description>All Patients who Received 1x400 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
        </group>
        <group group_id="P4">
          <title>Tramadol OAD 100mg</title>
          <description>All Patients who Received 1x100 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="141">Dose at which a patient spent the longest time.</participants>
                <participants group_id="P2" count="70">Dose at which a patient spent the longest time.</participants>
                <participants group_id="P3" count="25">Dose at which a patient spent the longest time.</participants>
                <participants group_id="P4" count="2">Two patients took 100 mg against instructions in protocol that the minimum daily dose was 200 mg.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tramadol OAD 200mg</title>
          <description>All Patients who Received 1x200 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
        </group>
        <group group_id="B2">
          <title>Tramadol OAD 300mg</title>
          <description>All Patients who Received 1x300 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
        </group>
        <group group_id="B3">
          <title>Tramadol OAD 400mg</title>
          <description>All Patients who Received 1x400 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
        </group>
        <group group_id="B4">
          <title>Tramadol OAD 100mg</title>
          <description>All Patients who Received 1x100 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="141"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="238"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="9.3"/>
                    <measurement group_id="B2" value="60.5" spread="8.8"/>
                    <measurement group_id="B3" value="58.5" spread="10.8"/>
                    <measurement group_id="B4" value="56.0" spread="5.7"/>
                    <measurement group_id="B5" value="60.0" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events: 12-months Safety Population</title>
        <description>Spontaneous adverse events were recorded for patients who received the same dose for at least 350 days. A treatment emergent adverse event (TEAE) was associated to the dose level on which a patient was 2 days prior to the TEAE. Only TEAEs which could be associated with the dose level on which the patient was for the longest time were considered.</description>
        <time_frame>12 months</time_frame>
        <population>Patients who received the same dose for at least 350 days (12 months)</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol OAD 200mg</title>
            <description>All Patients who Received 1x200 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol OAD 300mg</title>
            <description>All Patients who Received 1x300 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
          </group>
          <group group_id="O3">
            <title>Tramadol OAD 400mg</title>
            <description>All Patients who Received 1x400 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
          </group>
          <group group_id="O4">
            <title>Tramadol OAD 100mg</title>
            <description>All Patients who Received 1x100 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events: 12-months Safety Population</title>
          <description>Spontaneous adverse events were recorded for patients who received the same dose for at least 350 days. A treatment emergent adverse event (TEAE) was associated to the dose level on which a patient was 2 days prior to the TEAE. Only TEAEs which could be associated with the dose level on which the patient was for the longest time were considered.</description>
          <population>Patients who received the same dose for at least 350 days (12 months)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tramadol OAD 200mg</title>
          <description>All Patients who Received 1x200 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
        </group>
        <group group_id="E2">
          <title>Tramadol OAD 300mg</title>
          <description>All Patients who Received 1x300 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
        </group>
        <group group_id="E3">
          <title>Tramadol OAD 400mg</title>
          <description>All Patients who Received 1x400 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
        </group>
        <group group_id="E4">
          <title>Tramadol OAD 100mg</title>
          <description>All Patients who Received 1x100 mg Tramadol OAD Tablet daily for at Least 350 days.
OAD = Once-A-Day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinoid Tumour NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Disorder NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Essential Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="62" subjects_affected="26" subjects_at_risk="141"/>
                <counts group_id="E2" events="33" subjects_affected="16" subjects_at_risk="70"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" events="8" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="141"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="61" subjects_affected="34" subjects_at_risk="141"/>
                <counts group_id="E2" events="20" subjects_affected="10" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="141"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="45" subjects_affected="26" subjects_at_risk="141"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="141"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="51" subjects_affected="26" subjects_at_risk="141"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sweating increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submitting results communications, the investigator shall allow Labopharm at least 30 days to review the proposed communication. If the proposed publication/disclosure risks Labopharm's ability to patent any invention related to the study, the publication or disclosure will be modified or delayed to allow Labopharm to seek patent protection. This statement does not give Labopharm any editorial rights other than to restrict the disclosure of Labopharm's confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Regulatory Affairs</name_or_title>
      <organization>Labopharm Inc.</organization>
      <phone>1 450 686 1017</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

